PCI Synthesis, a custom chemical manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialist chemical products, has significantly increased its bench strength in quality control and r&d with the appointment of four experts in recent months.
Elie Saikali has joined the US firm as director of manufacturing from Lonza, where he held increasingly responsible positions in process r&d and ultimately held the title of product manager.
Mehdi Yazdi
Mehdi Yazdi has been hired as director of quality control and analytical services from Clariant Life Science Molecules, where he was QC manager.
Don Dickison has been appointed as director of business development. His prior experience includes roles at PRS Pharma and almost a decade and a half with Eli Lilly in various sales and sales management roles.
Don Dickison
In the role of director of cGMP Kilo Lab, Paul Nichols is responsible for early phase clinical drug substance development and manufacturing. He has joined PCI after several years at Array BioPharma, where he was senior research investigator. Before that, he worked at Abbott Labs as a research scientist.
Paul Nichols
